Search research articles
Contact Us
Filters
Showing results (91-100 of 165) with videos related to
Page
of 17
Sort By:
Clinical Chemistry
|
June 13, 1998
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease
M J Duffy, C Duggan, H E Mulcahy, et al.
Cancer
|
December 15, 1992
CA 15-3 in patients with locoregional and metastatic breast carcinoma
J G Geraghty, E C Coveney, F Sherry, et al.
Irish Journal of Medical Science
|
December 1, 1980
Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer
B Cantwell, M J Duffy, J J Fennelly, et al.
British Journal of Cancer
|
July 4, 1998
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry
S Kennedy, M J Duffy, C Duggan, et al.
Cancer Research
|
November 1, 1990
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
M J Duffy, D Reilly, C O'Sullivan, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
January 5, 1982
The free T3 index in familial TBG deficiency
R J Farrell, M J Duffy, G J Duffy, et al.
Cancer
|
January 1, 1983
CEA-like material in cytosols from human breast carcinomas. Correlation with biochemical and pathologic parameters
M J Duffy, M O'Connell, F O'Sullivan, et al.
Cancer
|
January 5, 1999
Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma
S G Shering, F Sherry, E W McDermott, et al.
Clinical Chemistry
|
August 1, 1992
Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer
A Nugent, E McDermott, K Duffy, et al.
International Journal of Cancer
|
May 29, 1995
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
C Duggan, T Maguire, E McDermott, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 165) with videos related to
Sort By:
Page
of 17
Clinical Chemistry
|
June 13, 1998
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease
M J Duffy, C Duggan, H E Mulcahy, et al.
Cancer
|
December 15, 1992
CA 15-3 in patients with locoregional and metastatic breast carcinoma
J G Geraghty, E C Coveney, F Sherry, et al.
Irish Journal of Medical Science
|
December 1, 1980
Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer
B Cantwell, M J Duffy, J J Fennelly, et al.
British Journal of Cancer
|
July 4, 1998
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry
S Kennedy, M J Duffy, C Duggan, et al.
Cancer Research
|
November 1, 1990
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
M J Duffy, D Reilly, C O'Sullivan, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
January 5, 1982
The free T3 index in familial TBG deficiency
R J Farrell, M J Duffy, G J Duffy, et al.
Cancer
|
January 1, 1983
CEA-like material in cytosols from human breast carcinomas. Correlation with biochemical and pathologic parameters
M J Duffy, M O'Connell, F O'Sullivan, et al.
Cancer
|
January 5, 1999
Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma
S G Shering, F Sherry, E W McDermott, et al.
Clinical Chemistry
|
August 1, 1992
Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer
A Nugent, E McDermott, K Duffy, et al.
International Journal of Cancer
|
May 29, 1995
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
C Duggan, T Maguire, E McDermott, et al.
Page
of 17